Joel Lewis - 16 Jan 2026 Form 4/A - Amendment Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
President and CEO, Director
Signature
Jack W. Callicutt
Issuer symbol
GALT
Transactions as of
16 Jan 2026
Net transactions value
$0
Form type
4/A - Amendment
Filing time
22 Jan 2026, 14:11:05 UTC
Date Of Original Report
21 Jan 2026
Previous filing
13 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LEWIS JOEL President and CEO, Director C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS Jack W. Callicutt 22 Jan 2026 0001725595

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock option (right to buy) Award $0 +91,000 $0.000000 91,000 16 Jan 2026 Common Stock 91,000 $3.04 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.
F3 The original Form 4 filed had an incorrect number of common stock options. This amendment presents the correct number of common stock options granted.